ES2149338T3 - Utilizacion de compuestos que liberan oxido nitrico para la fabricacion de un medicamento destinado al tratamiento de lesiones por reperfusion isquemica. - Google Patents

Utilizacion de compuestos que liberan oxido nitrico para la fabricacion de un medicamento destinado al tratamiento de lesiones por reperfusion isquemica.

Info

Publication number
ES2149338T3
ES2149338T3 ES95900491T ES95900491T ES2149338T3 ES 2149338 T3 ES2149338 T3 ES 2149338T3 ES 95900491 T ES95900491 T ES 95900491T ES 95900491 T ES95900491 T ES 95900491T ES 2149338 T3 ES2149338 T3 ES 2149338T3
Authority
ES
Spain
Prior art keywords
nitric oxide
injuries
compounds
manufacture
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95900491T
Other languages
English (en)
Inventor
David A Wink Jr
James B Mitchell
Angelo Russo
Murali C Krishna
Ingeborg Hanbauer
Matthew B Grisham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Louisiana State University
Original Assignee
US Department of Health and Human Services
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Louisiana State University filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2149338T3 publication Critical patent/ES2149338T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA INVENCION SUMINISTRA UN METODO PARA TRATAR LOS DAÑOS DEL TEJIDO INDUCIDOS POR RADICALES LIBRES DEL OXIGENO ASOCIADOS CON LESIONES DE REPERFUSION DE ISQUEMIA, EN EL QUE EL OXIDO NITRICO SE LIBERA HACIA LAS CELULAS/TEJIDO DE OBJETIVO A TRAVES DE LA ADMINISTRACION DE UN COMPUESTO QUE CONTIENE OXIDO NITRICO QUE ESPONTANEAMENTE LIBERA EL OXIDO NITRICO BAJO CONDICIONES FISIOLOGICAS SIN REQUERIR LA PRESENCIA DE OXIGENO.
ES95900491T 1993-11-02 1994-10-31 Utilizacion de compuestos que liberan oxido nitrico para la fabricacion de un medicamento destinado al tratamiento de lesiones por reperfusion isquemica. Expired - Lifetime ES2149338T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14661093A 1993-11-02 1993-11-02
PCT/US1994/012510 WO1995012394A1 (en) 1993-11-02 1994-10-31 Use of nitric oxide releasing compounds as protective agents in ischemia reperfusion injury

Publications (1)

Publication Number Publication Date
ES2149338T3 true ES2149338T3 (es) 2000-11-01

Family

ID=22518169

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95900491T Expired - Lifetime ES2149338T3 (es) 1993-11-02 1994-10-31 Utilizacion de compuestos que liberan oxido nitrico para la fabricacion de un medicamento destinado al tratamiento de lesiones por reperfusion isquemica.

Country Status (12)

Country Link
US (1) US5789447A (es)
EP (1) EP0726768B1 (es)
JP (1) JPH09508097A (es)
AT (1) ATE192922T1 (es)
AU (1) AU704173B2 (es)
CA (1) CA2175467A1 (es)
DE (1) DE69424560T2 (es)
DK (1) DK0726768T3 (es)
ES (1) ES2149338T3 (es)
GR (1) GR3034099T3 (es)
PT (1) PT726768E (es)
WO (1) WO1995012394A1 (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255277B1 (en) 1993-09-17 2001-07-03 Brigham And Women's Hospital Localized use of nitric oxide-adducts to prevent internal tissue damage
US6190704B1 (en) * 1994-09-23 2001-02-20 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Regulation of wound healing by nitric oxide
GB9423868D0 (en) * 1994-11-25 1995-01-11 Wellcome Found Compounds for use in medicine
US5726209A (en) * 1995-06-07 1998-03-10 Alliance Pharmaceutical Corp. Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir
DK0914103T3 (da) * 1996-04-05 2006-10-23 Gen Hospital Corp Behandling af hæmoglobinopati
US6232434B1 (en) 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US6656452B1 (en) 1997-10-21 2003-12-02 The General Hospital Corporation Use of inhaled NO as anti-inflammatory agent
EP1060174B1 (en) 1997-12-23 2004-09-22 Amersham Health AS Nitric oxide releasing chelating agents and their therapeutic use
US6103275A (en) * 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
US20040043068A1 (en) * 1998-09-29 2004-03-04 Eugene Tedeschi Uses for medical devices having a lubricious, nitric oxide-releasing coating
US20040151785A1 (en) * 1998-10-06 2004-08-05 Diamedica Inc. Method for treating insulin resistance through hepatic nitric oxide
US20070086954A1 (en) * 1998-11-23 2007-04-19 Miller Christopher C Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
CA2254645A1 (en) * 1998-11-23 2000-05-23 Pulmonox Medical Corporation Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
ES2147162B1 (es) * 1999-01-27 2001-03-16 Lacer Sa "s-nitrosotioles como agentes para el tratamiento de disfunciones circulatorias".
FR2794647A1 (fr) * 1999-06-11 2000-12-15 Centre Nat Rech Scient Compositions pharmaceutique comprenant du no ou au moins un compose capable de liberer ou d'induire la formation de no dans les cellules
HUP0202150A3 (en) * 1999-06-14 2003-10-28 Henry Ford Health System Detro Use of nitric oxide donors for inducing neurogenesis
US7135498B1 (en) 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
US7516742B2 (en) * 1999-11-24 2009-04-14 Cardinal Health 207, Inc. Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing
US6811965B2 (en) * 2000-03-08 2004-11-02 Yoram Vodovotz Kidney perfusion solution containing nitric oxide donor, inhibitor of NOS2, glutathione, gluconate and methods of use
US6270779B1 (en) * 2000-05-10 2001-08-07 United States Of America Nitric oxide-releasing metallic medical devices
FR2812200B1 (fr) * 2000-07-27 2003-01-03 Oxykines Therapeutics Composition contenant une proteine complexant le fer et un precurseur du metabolisme du monoxyde d'azote et/ou un donneur chimique de monoxyde d'azote ; et utilisations
JP2004506028A (ja) * 2000-08-11 2004-02-26 ホイットロック，デイビッド　アール． 一酸化窒素及び一酸化窒素前駆体の生産性を高めるアンモニア酸化細菌を含有する化合物並びにそれを利用する方法
US6432077B1 (en) * 2000-12-26 2002-08-13 Sensormedics Corporation Device and method for treatment of surface infections with nitric oxide
US7122018B2 (en) * 2000-12-26 2006-10-17 Sensormedics Corporation Device and method for treatment of wounds with nitric oxide
EP1436018A1 (en) * 2001-09-26 2004-07-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Nitric oxide-releasing coated medical devices and method of preparing same
US6703046B2 (en) * 2001-10-04 2004-03-09 Medtronic Ave Inc. Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use
GB0125222D0 (en) * 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
EP1472021A4 (en) * 2002-01-11 2008-04-16 David R Whitlock AMMONIAX OXIDIZING BACTERIA CONTAINING COMPOSITIONS AND USER METHOD THEREFOR
US20040038947A1 (en) * 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
WO2004017939A1 (ja) * 2002-08-20 2004-03-04 Terumo Kabushiki Kaisha 体内埋込医療器具
US6936639B2 (en) * 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
US7531133B2 (en) * 2002-09-10 2009-05-12 Pulmonox Technologies Corporation Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma
US20050009789A1 (en) * 2003-05-13 2005-01-13 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Service Cyclooxygenase inhibition with nitroxyl
DE602004008927T2 (de) 2003-07-09 2008-06-05 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Verwendung von nitritsalzen zur behandlung von kardiovaskulären erkrankungen
CA2539974A1 (en) * 2003-09-26 2005-04-07 David R. Whitlock Methods of using ammonia oxidizing bacteria
US20080085329A1 (en) * 2003-10-22 2008-04-10 Fred Hutchinson Cancer Research Center, Inc. Methods, Compositions and Devices for Inducing Stasis in Cells, Tissues, Organs, and Organisms
US20050136125A1 (en) * 2003-10-22 2005-06-23 Roth Mark B. Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
EP1718603A4 (en) 2004-02-09 2009-09-23 Noxilizer Inc MOLECULES RELEASING NITROGEN MONOXIDE
US20070232996A1 (en) * 2004-04-29 2007-10-04 Cube Medical A/S Balloon for Use in Angioplasty with an Outer Layer of Nanofibers
EP1755715A4 (en) * 2004-05-11 2010-03-24 Sensormedics Corp INTERMITTENT DETERMINATION OF GASEOUS NITRIC OXIDE
US8518457B2 (en) * 2004-05-11 2013-08-27 Pulmonox Technologies Corporation Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20070154570A1 (en) * 2004-09-29 2007-07-05 Miller Christopher C Use of nitric oxide in the treatment and disinfection of biofilms
MX2007013196A (es) * 2005-04-20 2008-01-18 Hutchinson Fred Cancer Res Metodos, composiciones y articulos de fabricacion para mejorar la supervivencia de celulas, tejidos, organos y organismos.
US8557300B2 (en) * 2005-05-19 2013-10-15 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
US20090214618A1 (en) 2005-05-27 2009-08-27 Schoenfisch Mark H Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
EP1909779A1 (en) * 2005-06-23 2008-04-16 Johns Hopkins University Thiol-sensitive positive inotropes
WO2007057763A2 (en) * 2005-11-18 2007-05-24 Pulmonox Technologies Corporation Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
US20070196327A1 (en) * 2005-12-06 2007-08-23 Amulet Pharmaceuticals, Inc. Nitric oxide releasing polymers
AU2014201936B2 (en) * 2006-10-06 2016-07-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Prevention of tissue ischemia, related methods and compositions
WO2008060785A2 (en) 2006-10-06 2008-05-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Prevention of tissue ischemia, related methods and compositions
US8079998B2 (en) * 2006-10-20 2011-12-20 Pulmonox Technologies Corporation Methods and devices for the delivery of therapeutic gases including nitric oxide
EP1939179A1 (en) 2006-12-28 2008-07-02 Lacer, S.A. Stable S-nitrosothiols, method of synthesis and use
WO2008089282A2 (en) * 2007-01-16 2008-07-24 Silver James H Sensors for detecting subtances indicative of stroke, ischemia, infection or inflammation
US20080193566A1 (en) * 2007-02-09 2008-08-14 Miller Christopher C Use of high dose concentrations of gaseous nitric oxide
WO2008134740A1 (en) * 2007-04-30 2008-11-06 The Trustees Of The University Of Pennsylvania System and method of resuscitation of a mammal
AU2008345034A1 (en) * 2007-12-27 2009-07-09 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide - donating compounds and uses thereof
CA2771389C (en) 2009-08-21 2019-04-09 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
CA2771308C (en) 2009-08-21 2020-01-21 Novan, Inc. Topical gels comprising nitric oxide releasing polysiloxane macromolecules
US20110160200A1 (en) * 2009-11-23 2011-06-30 Cardioxyl Pharmaceuticals, Inc. Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension
CN102753519B (zh) 2009-12-07 2015-08-05 约翰斯霍普金斯大学 二酰基化的羟基胺衍生物
ES2719101T3 (es) * 2009-12-07 2019-07-08 Univ Johns Hopkins Derivados de hidroxilamina N-acilados y derivados de hidroxilamina o-acilados
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118829A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same
WO2012154975A2 (en) * 2011-05-11 2012-11-15 Stc.Unm Nitric oxide/cgmp pathway inhibition of vla-4 related cell adhesion
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
LT2854841T (lt) 2012-06-04 2017-06-12 Diamedica Inc. Kalikreino 1 iš žmogaus audinio glikozilinimo izoformos
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
US11225640B2 (en) 2014-04-15 2022-01-18 Aobiome Llc Ammonia oxidizing bacteria for treatment of psoriasis
EP4219679A3 (en) 2014-04-15 2023-08-09 Aobiome LLC Ammonia-oxidizing nitrosomonas eutropha strain d23
US10662063B1 (en) * 2016-06-06 2020-05-26 University Of Puerto Rico Photosensitized release of nitric oxide
EP3523367A4 (en) 2016-10-07 2020-06-03 The University Of North Carolina At Chapel Hill HYPERRAMIFIED POLYESTERS MEDIATED BY S-NITROSOTHIOL
CA3048785A1 (en) 2017-01-03 2018-07-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
EP3592377A4 (en) 2017-03-09 2021-02-17 Diamedica Inc. DOSAGE FORMS OF TISSUE KALLIKREIN 1
WO2018178902A1 (en) 2017-03-28 2018-10-04 The University Of North Carolina At Chapel Hill Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto
EP3762039A4 (en) 2018-03-06 2021-12-22 The University of North Carolina at Chapel Hill NITRIC OXIDE RELEASING CYCLODEXTRINS AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDS AND RELATED PROCESSES
CN113383019B (zh) 2018-12-28 2023-11-17 北卡罗来纳大学教堂山分校 一氧化氮释放型抗菌聚合物和由其制成的支架和其相关方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3153094A (en) * 1959-06-10 1964-10-13 Du Pont Nitrosamine manufacture
US5039705A (en) * 1989-09-15 1991-08-13 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5212204A (en) * 1989-10-18 1993-05-18 The United States Of America As Represented By The Department Of Health And Human Services Antihypertensive compositions and use thereof
US5155137A (en) * 1990-09-20 1992-10-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Complexes of nitric oxide with polyamines
US5714511A (en) * 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs

Also Published As

Publication number Publication date
WO1995012394A1 (en) 1995-05-11
EP0726768A1 (en) 1996-08-21
EP0726768B1 (en) 2000-05-17
PT726768E (pt) 2000-11-30
ATE192922T1 (de) 2000-06-15
DK0726768T3 (da) 2000-10-02
JPH09508097A (ja) 1997-08-19
AU8130094A (en) 1995-05-23
GR3034099T3 (en) 2000-11-30
CA2175467A1 (en) 1995-05-11
AU704173B2 (en) 1999-04-15
US5789447A (en) 1998-08-04
DE69424560D1 (de) 2000-06-21
DE69424560T2 (de) 2001-01-18

Similar Documents

Publication Publication Date Title
ES2149338T3 (es) Utilizacion de compuestos que liberan oxido nitrico para la fabricacion de un medicamento destinado al tratamiento de lesiones por reperfusion isquemica.
HK1073788A1 (en) Medicament for the treatment of viral skin and tumour diseases
BR9206632A (pt) Sistema de penetração na pele melhorado para melhorada liberação tópica de drogas
PT671910E (pt) Utilizacao de derivados de adamantano no fabrico de um medicamento para o tratamento do glaucoma
DE3382641D1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
ES2071725T3 (es) Diesteres fosfato de acido ascorbico y tocoferilo para la inhibicion de la reaccion de maillard.
DE69939705D1 (de) Behandlung der pompeschen krankheit
MX9305248A (es) Compuestos de diarilpiperazinoacetamida.
BR9914385A (pt) Composição útil para o tratamento e prevenção de infecções protozoárias no homem e em animais, e, método de tratamento de uma infecção protozoária no homem e em animais
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
DE69111974D1 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
MY104521A (en) Treatment of depression.
KR900701278A (ko) 바이러스 감염 치료용 담즙산
MX9302818A (es) Agente para incrementar somatostatina o para inhibir la reduccion de somatostatina.
ZA962635B (en) Composition and process for prevention and treatment of cutaneous immediate hypersensitivity reactions
DE3275060D1 (en) Use of beta-(1-adamantyl)-alpha, alpha-dimethylethylamine for the manufacture of a medicament for the treatment of otitis externa in dogs
ES469020A1 (es) Procedimiento para la preparacion de nuevos 1-acil-2-hidroxi-1,3-diaminopropanos
ES8202561A1 (es) Un procedimiento para la produccion de 11,12-carbonato de eritromicilamina
AR030945A1 (es) Amidas de acido fenilciclohexanocarboxilico sustituido y su uso
AR026242A1 (es) Empleo de 2-amino-3,4-dihidro-quinazolinas para la preparacion de un medicamento para el tratamiento o profilaxis de enfermedades provocadas por estadosisquemicos
AR011115A1 (es) Compuestos sustituidos con sulfonamida, empleos para la preparacion de un medicamento y agente curativo
ES2072431T3 (es) D-acido aspartico beta-hidroxamato para el tratamiento de infecciones virales y de tumores.
HUP0000716A2 (hu) Fekélyes kolitisz és/vagy Crohn-féle betegség megelőzésére és kezelésére alkalmas gyógyszerkészítmény
ES2075797A1 (es) Derivados de acidos hidroxamicos terapeuticamente activos, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y el uso de dichos compuestos en medicina.
ES2064382T3 (es) Agente para el tratamiento de la enfermedad de raynaud.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 726768

Country of ref document: ES